Xbrane Biopharma press conference two new biosimilar candidates Transcript
Hello, everybody, and welcome to this webcast. It's with the reason of us introducing two new biosimilar candidates to our portfolio, and the initial development of these two products. My name is Martin, I'm the CEO of Xbrane Biopharma, and I have with me, Siavash, our COO and the Head of our biosimilar program. So we want to spend some time now to discuss our new portfolio and do the presentation of maybe 15, 20 minutes or so. And then we'll have a session of Q&A.
Okay. Yes, I am starting with a recap from our Capital Markets Day, which we held in May this year. (technical difficulty) quite some time to talk about the (technical difficulty) similar market and what we regard to attractiveness in the market. And above all, the strong growth, which is expected in this market coming years on the back of multiple biological drugs and their patent protection and being opened up (technical difficulty) similars. (technical difficulty) some -- one of the fastest-growing segments actually, in the pharmaceutical market. We believe it's a very good opportunity for us
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |